Controversies in the use of adjuvant trastuzumab (Herceptin)
- PMID: 17178019
- DOI: 10.1258/136218006779160517
Controversies in the use of adjuvant trastuzumab (Herceptin)
Abstract
Over-expression of the human epidermal growth factor receptor 2 (HER2) protein, amplification of the HER2 gene or both occur in 15-25% of breast cancers and are associated with aggressive tumour behaviour. Trastuzumab (Herceptin), a humanized murine monoclonal antibody against the HER2 protein, has been shown to benefit patients with HER2-positive metastatic breast cancer when administered alone or in combination with chemotherapy. When to start therapy, the duration of treatment, adjuvant chemotherapy regimens and cardiotoxicity issues are examined.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous